Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab?

Featuring James Del Rosso, DO | Clinical Advisor | Adjunct Clinical Professor (Dermatology) Touro University Nevada Henderson, NV Research Director/ Principal Investigator/ Clinical Dermatologist JDR Dermatology Research Las Vegas, NV | Published April 28, 2022